Clinical Trials Logo

Clinical Trial Summary

To assess the reliablity and validity of 2 new iris cameras in the assement of corneal opacification in mucopolysaccharidoses


Clinical Trial Description

The mucopolysaccharidoses (MPS) are a group of disorders resulting from accumulation of glycosaminoglycans within various tissues including the eye. This can result in visual loss from corneal opacification. The assessment of corneal opacification is extremely subjective and based on a clinician grading this during slit lamp examination. There can be a significant variability and can prove problematic particularly in clinical trials assessing if corneal opacification is affected by potential new treatments. The use of imaging could facilitate objective measurement of corneal clouding. A previous study using an iris camera and image analysis to provide a corneal opacification measure score (COM score) demonstrated that it can be used in children with MPS, however it still had limitations- as the system is fully automated, if certain conditions are not met an image is not captured. This can be an issue in younger children who may not be cooperative, and limited its use in younger patient populations. It is anticipated that these limitations can be addressed by employing a newer iris camera (IriShield MK2120UL). The new camera's advantage is that it takes images monocularly, therefore only the eye under question needs to be aligned. We will also assess a new manual system (IRcamNew) which takes images whenever the shutter is manually pressed. This would be useful in children who cannot fixate with one eye, and can also be used when the child is examined under general anaesthetic which is commonly done in paediatric ophthalmology. If proven to be comparable to the existing iris camera (IriscamOrig) in terms of validity and reliability, the added benefits of these new iris cameras can open its use in a wider range of patient populations - for instance, in paediatric clinical trials-, as well as allowing longitudinal tracking of corneal clouding from early childhood well into adulthood. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05354219
Study type Observational
Source Manchester University NHS Foundation Trust
Contact Jane Ashworth, MD
Phone 0161 276 1234
Email jane.ashworth@mft.nhs.uk
Status Recruiting
Phase
Start date March 8, 2023
Completion date September 8, 2023

See also
  Status Clinical Trial Phase
Terminated NCT01675674 - Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics N/A
Recruiting NCT05063435 - Cardiovascular Structure and Function in the Mucopolysaccharidoses
Active, not recruiting NCT03632213 - Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI Phase 2
Recruiting NCT02583152 - New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis N/A
Completed NCT04112602 - Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis
Completed NCT01586871 - Carotid Structure and Function in MPS Syndromes: A Multicenter Study of the Lysosomal Disease Network
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Not yet recruiting NCT03017677 - A Cross-specialty Collaboration Platform for Mucopolysaccharidosis Confirmative Diagnosis N/A
Completed NCT04491747 - Assessment of Factors That Affected Respiratory Parameters in Mucopolysaccharidoses Patients
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Not yet recruiting NCT04637646 - Evaluation of Cardiac Affections in Patients With Mucopolysaccharidosis (MPS) in Assuit University Children Hospital (AUCH)
Completed NCT01521429 - Longitudinal Study of Bone Disease in Children With Mucopolysaccharidoses (MPS) I, II, and VI